{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-23-018328","form_type":"8-K","ticker":"HIND","cik":"0001427570","company_name":"Vyome Holdings, Inc","filed_at":"2023-11-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:29.039640+00:00","generated_at":"2026-06-08T06:25:06.475369+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"ReShape Q3 revenue down 21% to $2.2M; announces $8M cost cuts for 2024","bullets":["Revenue $2.2M in Q3 2023, down from $2.8M in Q3 2022; nine-month revenue $6.7M, down 17%.","Gross profit margin fell to 59.8% from 75.1% in Q3; non-GAAP adjusted EBITDA loss improved to $2.9M from $4.2M.","Cash $1.5M at Sept 30; raised $2.8M net in Oct public offering; no debt.","Targeting ~$8M cost reductions in 2024 including RIF, aiming >40% cut in operating expenses.","Exclusive license deal with Biorad for Obalon in India subcontinent; FDA decision on Lap-Band 2.0 Flex expected by year-end."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-23-018328","json":"https://secwatch.observer/filing/0001558370-23-018328.json","markdown":"https://secwatch.observer/filing/0001558370-23-018328.md","text":"https://secwatch.observer/filing/0001558370-23-018328.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1427570/000155837023018328/0001558370-23-018328-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1427570/000155837023018328/rsls-20231108x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T06:25:06.475369+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"fe1c6375f156b690e570eb6d3d851ca49828a7f7","claim":"Vyome Holdings, Inc reported financial results for three and nine months ended September 30, 2023.","evidence_excerpt":"On November 8, 2023, ReShape Lifesciences Inc. (the “Company”) issued a press release announcing its financial results for the three and nine months ended September 30, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1427570/000155837023018328/0001558370-23-018328-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"three and nine months ended September 30, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}